Background: The 70-gene prognosis signature has strong prognostic value in nodenegative breast cancer, independent of established prognostic factors. It is unclear whether all node-negative patients should receive a signature result. We therefore evaluated its additional prognostic information to a combination of established prognostic guidelines.
Introduction
The majority of patients with lymph node-negative breast cancer can be cured by surgery or radiotherapy alone without any potential toxic and costly adjuvant systemic treatment.
1 Identi¿ cation of patients who would bene¿ t from adjuvant systemic treatment is crucial. A 70-gene prognosis signature was identi¿ ed by gene expression pro¿ ling of 78 breast cancer tumours selected from the tissue bank of the Netherlands Cancer Institute (Amsterdam, the Netherlands).
2 This prognosis signature appeared a strong independent prognostic factor in three retrospective validation studies in comparison with clinicopathological factors in multivariate analysis. [3] [4] [5] To aid the prognosis signature's diagnostic use, a customized microarray (MammaPrint TM ) was commercially developed by Agendia (Amsterdam, the Netherlands).
6 Several questions remain regarding the optimal integration of this prognosis signature into routine clinical practice. In 2007, the results of the RASTER (microarRAy prognoSTics in breast cancER) study provided evidence that the procedures for acquiring tumour material for genomics (e.g. collecting frozen samples) -the major obstacle for broad "real time" application in a community-based setting -are feasible. Whether patients will bene¿ t from the use of the 70-gene prognosis signature versus classical prognostic factors is addressed in the ongoing MINDACT (Microarray in Node-negative Disease May Avoid Chemotherapy) trial; an international prospective randomised trial launched in 2007 by the TRANSBIG consortium in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC). 8;9 The most important issue studied in the MINDACT trial is to show whether the prognosis signature safely selects fewer patients for adjuvant chemotherapy compared with traditional prognostic guidelines and indexes. 8;9 It will however take several years before suf¿ cient follow-up will be collected and results will be available for clinical practice. Meanwhile, the additive value of the 70-gene prognosis signature in nodenegative patients remains a matter of debate. An important question in this respect is for which subgroups of patients the 70-gene prognosis signature could be of value in clinical practice and how this signature should be integrated with existing tools that are used to guide decisions on adjuvant systemic treatment. We evaluated three patient series, in which a 70-gene prognosis signature result was available, to address these questions.
Methods

Patients
For this observational study, the clinical, pathological and follow-up data were analysed from three consecutive patient series diagnosed between 1984 and 2006. The ¿ rst series consisted of 151 patients of a validation study regarding the 70-gene prognosis signature ('NEJM-series'); 3;5;10 the second series consisted of 123 patients of another validation study of the 70-gene prognosis signature ('validation-series'); 5 the third series consisted of 427 patients from the RASTER-study ('the RASTER-series').
8
Female patients younger than 61 years with primary breast cancer diagnosed between 1984 and 2006, who had received adequate local therapy for unilateral lymph node-negative invasive breast cancer (pT1-4N0M0) in hospitals in the Netherlands, were included. Patients with prior malignancies (with the exception of basal cell carcinomas and cervical dysplasia) or neoadjuvant systemic treatment were not considered eligible. The 70-gene prognosis signature (MammaPrint   TM   ) was available in all patients. A patient's (good or poor) 70-gene prognosis signature was determined on frozen samples at Agendia Laboratories blinded to clinical outcome data. 6 The analysis was performed on 701 patients, in whom clinical, pathological and follow-up data were available. If central review of paraf¿ n-embedded tumour samples was performed, these data were used (n=695); in six other cases the data of the original pathological examination were used. 16;17 A low clinical risk was de¿ ned as a 10-year overall survival probability of at least 90%, because bene¿ t of adjuvant systemic treatment is supposed to be less than 5% in these patients assuming that this treatment reduces the mortality risk with approximately 50%. 1 Statistical analysis Differences in patient and tumour characteristics between the three patient series were tested using the Pearson Chi-Square test. In case of ordinal variables (age and histological grade) with more than two groups, we tested for trends (using CochranArmitage test). A signi¿ cant ¿ nding was de¿ ned as a P-value smaller than 0.05. Level of agreement between clinical-risk assessment and prognosis signature, as well as among the mentioned clinical-risk assessment based on St Gallen guidelines, Adjuvant Online Software and NPI, was expressed by means of a Cohen's kappa. A kappa of one indicates perfect agreement, and a kappa of zero indicates no agreement over chance. Survival analyses were performed with data of patients who had not received any form of adjuvant systemic treatment, and had been treated for their breast cancer at least 5 years before the data collection was performed for this study in order to guarantee substantial follow-up. All these patients (NEJM-(n=151) and validation-series (n=71)) had been treated at the Netherlands Cancer Institute (Amsterdam, the Netherlands). These patients form a consecutive patient series from one institute. The two survival endpoints were time from surgery to distant metastasis as ¿ rst event (DMFS), which was the endpoint used to identify the 70-gene signature 2 ; and overall survival (OS), de¿ ned as time from surgery to death. In the analysis of distant metastasis, patients whose ¿ rst failure was distant metastasis were counted as failures; all other patients were censored at the date of their last follow-up, death, contralateral breast cancer, other second primary or loco-regional recurrence. Kaplan Meier survival curves 18 were drawn and compared using a log-rank test (Mantel-Cox) . 19 Values are expressed as percentages ± standard error (SE). Logistic regression analysis was performed to estimate the additional value of the 70-gene prognosis signature to traditional prognostic clinicopathological risk factors (age, tumour size, histologic grade, ER, progesterone receptor, and ERBB2-receptor). A traditional prognostic model, based on all above mentioned prognostic factors, was compared to a new model also including the prognosis signature. The change in log-likelihood was tested using a Chi-square test. Calculations were performed using the statistical package SPSS (SPSS for Windows, Release 15.0.1; Chicago: SPSS Inc.).
Results
Patients
Patient characteristics are summarised in table 1. Mean age of 701 patients was 47 years (SD 6.5, range 26-60). Mean age in NEJM-patients was 44 (SD 5.6, range 28-52), in validation-patients 47 years (SD 6.5, range 26-54), and in RASTER-patients 47 years (SD 6.5, range 27-60). Patients of the validation-and RASTER-series were older compared to patients in the NEJM-series. Mean tumour diameter was 19 mm (SD 8, range 2-80). Mean tumour diameter in patients of the NEJM-series was 22 mm (SD 9, range 2-50), in the validation-patients 20 mm (SD 8, range 5-50) and in RASTERseries 17 mm (SD 8, . Adjuvant systemic treatment was administered to 45% (314/701) of the patients; 14% (97/701) chemotherapy, 11% (75/701) endocrine treatment and 20% (142/701) both. Forty-nine percent (343/701) of the patients had a tumour with a good and 51% (358/701) with a poor prognosis signature.
Clinical risk indexes and prognosis signature According to the Adjuvant! Online, the St Gallen guidelines and NPI respectively 71%, 83%, and 49% of the patients were assessed as moderate or high risk. In 37% of the patients (259/701; kappa 0.25; table 2) the clinical risk according to the Adjuvant! Online was discordant with the prognosis signature (webtable 1A).If St Gallen guidelines or NPI were used, respectively in 38% (261/696; kappa 0.25; table 2) and 27% (186/701; kappa 0.47; table 2) of the patients the risk assessment was discordant with the prognosis signature (webtable 1B-1C). Webtable 2 shows the discordance between Adjuvant! Online, St Gallen guidelines, and Nottingham Prognostic Index (N=701).
8 Table 1 : Relations of clinical and pathological variables with 70-gene prognosis signature for all patients (N=701) and for untreated NKI patients of the NEJM-and validation-series (N=186). Survival analyses and regression analyses in untreated NKI patients Sixteen percent (36/222) of the NKI patients of the NEJM and validation series received some form of adjuvant systemic treatment and were excluded for the survival analyses. Patient and tumour characteristics of the 186 untreated NKI patients are summarised in table 1. Mean age was 45 years (SD 6) and mean tumour diameter was 22 mm (SD 8). Median follow up in the untreated NKI patients was 9.0 years (interquartile range (IQR) 7.0). During follow up 84 cancer related ¿ rst events occurred [11 local recurrences (13%), 8 regional recurrences (10%), 48 distant metastases (57%), 12 contralateral breast cancers (14%), and 5 second primary cancers (6%; other types of cancer)]. Fifty-three (28%) patients died (49 breast cancer related and 4 due to other cancers). At 10 years the probability of remaining free of distant metastasis (as ¿ rst event) was 88 % (SE 4%) for good and 55 % (SE 6%) for poor prognosis signature patients. The 10-year survival probability was 91% (SE 3%) for good and 56 % (SE 5%) for poor prognosis signature patients. The performance of regression models to predict either DMFS or OS based on clinical parameters (age, tumour size, histologic grade, ER, progesterone receptor, and ERBB2 receptor status) signi¿ cantly improved if the 70-gene signature was added to the respective models. This was shown by statistically signi¿ cant change in log likelihood for both DMFS (p<0.001) and OS (p=0.005).
Additional value of prognosis signature, subgroup analyses Only six percent (10/156; table 1) of all patients with an ER negative tumour had a good prognosis signature. Therefore the additional value of the prognosis signature is very limited in ER negative patients. The additional value of the 70-gene prognosis signature was therefore studied in untreated patients with an ER positive tumour. Median follow-up of these patients was 9.1 years (IQR 6.4). Fifty-¿ ve percent (76/139) had a tumour with a good and 45% (63/139) with a poor prognosis signature. Three patient groups were analysed: I) patients with a concordant low clinical risk for the three prognostic risk indexes (Adjuvant! Online, St Gallen guidelines and Nottingham Prognostic Index) (the so-called low-low-low group); II) patients with a concordant high clinical risk for the three prognostic indexes (the so-called high-highhigh group); and III) patients in whom the three prognostic indexes were discordant (the so-called discordant group). A high-high-high clinical risk pro¿ le was associated with younger age, a larger tumour and with a poor prognosis signature (table 3) . One in four patients (23%; 7/31) with a low-low-low clinical risk pro¿ le had a poor prognosis signature tumour. Vice versa, one in four patients (27% (13/49); with a high-high-high clinical risk had a good prognosis signature tumour. In patients with clinical discordant risk pro¿ le, 66% (39/59) had a good and 34% (20/59) a poor prognosis signature tumour (P<0.001).
For each clinical risk group (low-low-low, high-high-high and discordant) the additional value of the prognosis signature within the subgroup was studied. Figure 1 shows the Kaplan Meier curves with DMFS and OS for the three patient groups.
The 10-year estimated DMFS and the OS percentages for patients with a lowlow-low clinical risk were 83% (SE3%) and 97% (SE 3%). For the small number of patients in these subgroups, the prognosis signature distinguishes within the low-low-low clinical risk patients, the good from the poor prognosis patients despite small numbers (¿ gure 1A and B). The low-low-low clinical risk patients with a poor prognosis signature outcome have a 10-year estimated DMFS of 70% (SE 18%) versus 87% (SE 9%) in good prognosis signature patients. Their estimated OS is 86% (SE 13%) and 100%, respectively. 8 Table 3 : Clinical and pathological variables of untreated NKI patients with an ER positive tumour of the NEJM-and validation-series (N=139) strati¿ ed for a concordant low clinical risk based on Adjuvant! Online, St Gallen guidelines and Nottingham Prognostic Index, a concordant high risk for these three prognostic indexes or a discordant clinical risk.
The 10-year DMFS and OS in patients with a discordant clinical risk is 82% (SE 6%) and 79% (6%) respectively. The good prognosis signature patients with a discordant clinical risk have a 10-year estimated DMFS of 91% (SE 5%) versus 63% (SE 13%) in poor prognosis signature patients (¿ gure 1C and D). The 10-year estimated OS for good prognosis signature patient is 88% (SE 6%) versus 58% (15%) for poor prognosis signature patients. The DMFS survival is higher than the OS because 2 out of 11 deaths in this subgroup were due to another cancer without having had breast cancer related distant metastasis before developing the other cancer.
The 10-year DMFS and OS in high-high-high clinical risk patients is 53% (8%) and 60% (8%) respectively. In these patients the 10-year estimated DMFS and OS for both good (respectively, 77% (2%) and 77% (12%)) and poor (respectively, 45% (10%) and 53% (9%)) prognosis signature outcome was less than 80% (¿ gure 1E and 3F). Obtaining the prognosis signature in clinical high-high-high patients would not alter the adjuvant systemic treatment advice. The additional value of the prognosis signature to any combination of two of the three mentioned clinical risk indexes instead of three was studied as well. Table 4 shows that a combination of the NPI with any of the other two risk indexes instead of three risk indexes performs equally well and is in fact similar to a combination of all three indexes together: in concordant low-low and in discordant patients, the estimated OS in poor prognosis and good prognosis is <80% and 85%, respectively. Thus, in these patients the prognosis signature adds clinical useful prognostic information that may alter treatment decision. Also, the prognosis signature adds no prognostic information in high-high risk patients as estimated 10-year DMFS and OS are less than 80% for both a good and a poor prognosis signature.
8 Table 4 : Analyses in untreated NKI patients with an ER positive tumour of the NEJM-and validation series (n=139). The estimated 10-year distant metastasis as ¿ rst event free survival (A) and overall survival (B) for patients with a low-low (-low), high-high (-high) and discordant clinical risk pro¿ le, and the additional value of the 70-gene prognosis signature on the survival estimates.
Discussion
The microarray-based 70-gene prognosis signature (MammaPrint   TM   ) is a validated molecular test for all lymph node-negative breast cancer patients. The prognosis signature appeared to be an independent additional prognostic test in the logistic regression analyses in untreated lymph node-negative patients in this study. More importantly, this study helped to identify patients for whom the additional value of the prognosis signature to a combination of clinical risk indexes is high and for whom it is limited. The prognosis signature was discordant with clinical risk based on the Adjuvant! Online, the St Gallen guidelines and NPI in approximately one third (27-38%) of the patients. This implies that in one third of the patients the prognosis signature would assign the patients to a different prognosis category and as a result these patients may receive a different adjuvant systemic treatment advice. This study shows that only 6% of patients with ER-negative tumours have a good prognosis signature. In view of this, the prognosis signature adds only very limited prognostic information in ER-negative tumours. In untreated patients with an ER-positive tumour, a combined clinical risk assessed using two or three prognostic indexes (e.g. NPI with either Adjuvant! Online or St Gallen guidelines, or all three together), can classify a patient's risk as concordant low-low (-low), concordant high-high (-high) or discordant for these guidelines. Our results show that the additional value of the 70-gene prognosis signature in patients with a clinical high-high (-high) is limited as estimated 10-year DMFS and OS are less than 80% for both a good and a poor prognosis signature. Obtaining the prognosis signature in clinical high-high (-high) patients will thus not alter the adjuvant systemic treatment advice. In patients with a concordant low-low-low and discordant clinical risk comprising 65% (90/139) of the ER positive, lymph node-negative breast cancer patients, the prognosis signature has discriminative value as outlined in ¿ gure 2. The prognosis signature adds prognostic information as well in above mentioned combinations of two prognostic indexes for concordant low and discordant patients.
For the purpose of this study we have assumed that adjuvant systemic therapy bene¿ ts mostly patients with a 10-year mortality risk of more than 10%.
1 Therefore a 10-year estimated OS of less than 90% was used as cut-off to consider adjuvant chemotherapy. The vast majority of these patients will also receive endocrine treatment which will lead to a relative risk reduction of 50% in this patient group.
1
In the MINDACT trial, ER positive patients are considered low risk if their 10-year survival is at least 88%.
8;9 This cut-off was chosen to reÀ ect the fact that in current clinical practice patients with ER-positive tumours receive adjuvant endocrine therapy (with an estimated absolute 10-year bene¿ t of approximately 4% overall). Based on the presented results, if patients have a low-low-low clinical risk and a poor prognosis signature outcome or a discordant clinical risk and a good prognosis signature outcome, advising only endocrine treatment may be considered (¿ gure 2), in particular when a patient classi¿ es as 'completely endocrine responsive' according to St Gallen de¿ nitions.
11
The 21-gene recurrence score (Oncotype DX assay) is another prognostic geneexpression pro¿ le and quanti¿ es the likelihood of distant recurrence in patients treated with tamoxifen who have node-negative, ER positive breast cancer using paraf¿ n-embedded material. [20] [21] [22] Paik et al compared the performance of the 21-gene recurrence score with the histological grading performance of three pathologists.
20
They concluded that the 21-recurrence score was more robust in the multivariate analyses as substantial inter-observer variation (discordance 57%, kappa 0.23-0.36) existed between the three pathologists in that study. As long as inter-observer variation between pathologists is large, 20;23 however, there is a need for molecular prognostic tests such as the 70-gene prognosis signature.
Another important issue before genomic pro¿ ling can be integrated in daily clinical practice is the socioeconomic assessment of the introduction in clinical practice, in terms of cost-effectiveness, expectations and attitude of patients and clinicians towards genomics. The answers to these questions will be available in several years when the results of the MINDACT trial become available. Until then, collecting frozen tumour samples should be standard clinical practice in hospitals as to not only boost the expected application of this prognosis signature in clinical practice, but also to address other major issues including the identi¿ cation of gene expression signatures predictive of response to a speci¿ c chemotherapy, hormonal therapy and targeted therapy regimens. This is crucial if we want to accelerate the transition between empirical and tailored oncology.
8
We conclude that the 70-gene prognosis signature adds prognostic information in patients with lymph node-negative and ER positive breast cancer with a predominant low or discordant clinical risk based on Adjuvant! Online, St Gallen guidelines, and the Nottingham Prognostic Index. Contributors JM Bueno-de-Mesquita, GS Sonke, SC Linn, and MJ Van de Vijver were responsible for the study design. JM Bueno-de-Mesquita coordinated and performed the study. JM Bueno-de-Mesquita performed the data collection. JM Bueno-de-Mesquita and GS Sonke performed the statistical data analysis. JM Bueno-de-Mesquita, GS Sonke, SC Linn, and MJ Van de Vijver took part in data interpretation and manuscript writing. All authors were involved in reviewing the manuscript. The corresponding author (SC Linn) had access to all data in the study and he had ¿ nal responsibility for the decision to submit for publication.
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